Enhanced efficacy of CKD-516 in combination with doxorubicin: Pre-clinical evaluation using a hepatocellular carcinoma xenograft model

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1715-1722

  Kim, Young Il ^a   Kim, Kyung Won ^b   Lee, Han Kyu ^a   Park, Jisuk ^a   Chung, Jin Wook ^a   Youn, Hyewon ^c   Kim, Soo Jin ^d   Kim, Dal Hyun ^d   Tseng, Jen Chieh ^e   Lee, Jeong Min ^a  

^a Seoul National University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Chong Kun Dang Research Institute   (South Korea)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CKD 516; Doxorubicin; Hepatocellular carcinoma; Tubulin binding agents; Vascular disrupting agent

Indexed keywords

CDK 156; DOXORUBICIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; N-(4-(3-(1H-1,2,4-TRIAZOL-1-YL)-4-(3,4,5-TRIMETHOXYBENZOYL)PHENYL)THIAZOL-2-YL)-2-AMINO-3-METHYLBUTANAMIDE; BENZOPHENONE DERIVATIVE; DRUG DERIVATIVE; N (4 (3 (1H 1,2,4 TRIAZOL 1 YL) 4 (3,4,5 TRIMETHOXYBENZOYL)PHENYL)THIAZOL 2 YL) 2 AMINO 3 METHYLBUTANAMIDE; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; REBOUND; TUMOR NECROSIS; TUMOR XENOGRAFT; ANIMAL; CKD-516; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; LIVER TUMOR; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUBULIN-BINDING AGENTS; TUMOR CELL LINE; TUMOR VOLUME; VASCULAR-DISRUPTING AGENT;

CKD-516; DOXORUBICIN; HEPATOCELLULAR CARCINOMA; TUBULIN-BINDING AGENTS; VASCULAR-DISRUPTING AGENT;

ANIMALS; APOPTOSIS; BENZOPHENONES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HUMANS; LIVER NEOPLASMS; MICE; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR BURDEN; VALINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902270821     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pellegrini F and Budman DR: Review: Tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23: 264-273, 2005.
2. Mason RP, Zhao D, Liu L, Trawick ML and Pinney KG: A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integr Biol 3: 375-387, 2011.
3. Delmonte A and Sessa C: AVE8062: A new combretastatin derivative vascular-disrupting agent. Expert Opin Investig Drugs 18: 1541-1548, 2009.
4. Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D and O'Brien PE: Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7: 1052-1060, 2001.
5. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ and Hill SA: ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247-7253, 2002.
6. McKeage MJ and Baguley BC: Disrupting established tumor blood vessels: An emerging therapeutic strategy for cancer. Cancer 116: 1859-1871, 2010.
7. Lee J, Bae S, Lee SH, Choi H, Kim YH, Kim SJ, Park GT, Moon SK, Kim DH, Lee S, Ahn SK, Choi NS and Lee KJ: Discovery of a potent tubulin polymerization inhibitor: synthesis and evaluation of water-soluble prodrugs of benzophenone analog. Bioorg Med Chem Lett 20: 6327-6330, 2010.
8. Lee J, Kim SJ, Choi H, Kim YH, Lim IT, Yang HM, Lee CS, Kang HR, Ahn SK, Moon SK, Kim DH, Lee S, Choi NS and Lee KJ: Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem 53: 6337-6354, 2010.
9. Kim KW, Lee JM, Jeon YS, Lee IJ, Choi Y, Park J, Kiefer B, Kim C, Han JK and Choi BI: Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI. Invest New Drugs 31: 1097-1106, 2013.
10. Sugimachi K, Tanaka S, Terashi T, Taguchi K, Rikimaru T and Sugimachi K: The mechanisms of angiogenesis in hepatocellular carcinoma: Angiogenic switch during tumor progression. Surgery 131: S135-S141, 2002.
11. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P and Cheng AL: Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 81(Suppl 1): 158-164, 2011.
12. Ansari B, Coates PJ, Greenstein BD and Hall PA: In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170: 1-8, 1993.
13. de Torres C, Munell F, Ferrer I, Reventos J and Macaya A: Identification of necrotic cell death by the TUNEL assay in the hypoxic-ischemic neonatal rat brain. Neurosci Lett 230: 1-4, 1997.
14. Weidner N: Tumour vascularity and proliferation: Clear evidence of a close relationship. J Pathol 189: 297-299, 1999.
15. Avila MA, Berasain C, Sangro B and Prieto J: New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884, 2006.
16. Hernandez-Gea V, Toffanin S, Friedman SL and Llovet JM: Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144: 512-527, 2013.
17. Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN and Theise ND: Neoangiogenesis and sinusoidal 'capillarization' in dysplastic nodules of the liver. Am J Surg Pathol 22: 656-662, 1998.
18. Lee TY and Gotlieb AI: Microfilaments and microtubules maintain endothelial integrity. Microsc Res Tech 60: 115-127, 2003.
19. Siemann DW, Mercer E, Lepler S and Rojiani AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99: 1-6, 2002.
20. Wang H, Marchal G and Ni Y: Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World J Radiol 3: 1-16, 2011.
21. Vaupel P and Hockel M: Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance. Int J Oncol 17: 869-879, 2000.
22. Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, Vandecaveye V, Peeters R, Bosmans H, Hermans R, Marchal G and Ni Y: Treatment of rodent liver tumor with combretastatin A4 phosphate: Noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 44: 44-53, 2009.
23. Nelkin BD and Ball DW: Combretastatin A4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 8: 157-160, 2001.
24. Mitrus I, Sochanik A, Cichon T and Szala S: Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors. Acta Biochim Pol 56: 161-165, 2009.